Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 1, 2012, Pages 89-93

  Slenker, Amy K ^a   Keith, Scott W ^a   Horn, David L ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b 3805 Old Easton Road ^*  (United States)

Author keywords

Bone; Candida; Fungal; Infection; Osteomyelitis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; POSACONAZOLE; VORICONAZOLE;

ABDOMINAL SURGERY; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA OSTEOMYELITIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CENTRAL VENOUS CATHETER; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; SPECIES DIFFERENCE; SYSTEMATIC REVIEW; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; COMORBIDITY; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; OSTEOMYELITIS; RISK FACTORS; SEX DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860745858     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.02.004     Document Type: Article

References (37)

1. Anaissie E.J., Darouiche R.O., Abi-Said D., Uzun O., Mera J., Gentry L.O., et al. Management of invasive candidal infections: results of a prospective, randomized multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996, 23:964-972.
2. Blumberg H.M., Jarvis W.R., Soucie J.M., Edwards J.E., Patterson J.E., Pfaller M.A., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS Prospective Multicenter Study. Clin Infect Dis 2001, 33:177-186.
3. Cornely O.A., Lasso M., Betts R., Klimko N., Vazquez J., Dobb G., et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemo 2007, 60:363-369.
4. Fraser V.J., Jones M., Dunkel J., Storfer S., Medoff G., Dunagan W.C. Candidemia in a tertiary care hospital: epidemiology, risk factors and predictors of mortality. Clin Infect Dis 1992, 15:414-421.
5. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
6. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703.
7. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., Rex J.H. Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693-715.
8. Leleu G., Aegerter P., Guidet B., Collegedes Utilisateurs de Base de Donnees en Reanimation Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002, 17:168-175.
9. Miller L.G., Hajjeh R.A., Edwards J.E. Estimating the cost of nosocomial candidemia in the United States. Clin Infect Dis 2001, 32:1110.
10. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.
11. Morgan J., Meltzer M.I., Plikaytis B.D., Sofair A.N., Huie-White S., Wilcox S., et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26:540-547.
12. National Nosocomial Infections Surveillance National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999, 27:520-532.
13. Ostrosky-Zeichner L., Pappas P.G. Invasive candidiasis in the intensive care unit. Crit Care Med 2006, 34(3):857-863.
14. Ostrosky-Zeichner L., Rex J.H., Bennett J., Kullberg B.J. Deeply invasive candidiasis. Infect Dis Clin North Am 2002, 16:821-835.
15. Pappas P.G. Invasive Candidiasis. Infect Dis Clin North Am 2006, 485-506.
16. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
17. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
18. Peres-Bota D., Rodriguez-Villalobos H., Dimopoulos G., Melot C., Vincent J.L. Potential risk factors for infection with Candida spp. in critically ill patients. Clin Microbio Infect 2004, 10:550-555.
19. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46:150-156.
20. Pfaller M.A., Diekema D.J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002, 40:3551-3557.
21. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbio Rev 2007, 20:133-163.
22. Pfaller M.A., Jones R.N., Doern G.V., Fluit A.C., Verhoef J., Sader H.S., et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 1999, 35:19-25.
23. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., Wenzel R.P. National surveillance of nosocomial bloodstream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998, 30:121-129.
24. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., Doern G.V., Brandt M.E., et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 1999, 33(4):217-222.
25. Pfaller M.A., Messer S.A., Houston A., Rangel-Frausto M.S., Wiblin T., Blumberg H.M., et al. National Epidemiology of Mycoses Survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 1998, 31:289-296.
26. Phillips P., Shafran S., Garber G., Rotstein C., Smaill F., Fong I., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in nonneutropenic patients. Eur J Clin Microbiol Infect Dis 1997, 16:337-345.
27. Rangel-Frausto M.S., Wiblin T., Blumberg H.M., Saiman L., Patterson J., Rinaldi M., et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units. Clin Infect Dis 1999, 29:253-258.
28. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482.
29. Rentz A.M., Halpern M.T., Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998, 27:781-788.
30. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., van der Horst C.M., Edwards J.E., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994, 331:1325-1330.
31. Rex J.H., Pappas P.G., Karchmer A.W., Sobel J., Edwards J.E., Hadley S., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic patients. Clin Infect Dis 2003, 36:1221-1228.
32. Rex J.H., Pfaller M.A., Barry A.L., Nelson P.W., Webb C.D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995, 39:40-44.
33. Steinbach W.J., Perfect J.R. Newer antifungal therapy for emerging fungal pathogens. Int J Infect Dis 2003, 7:5-20.
34. Wenzel R.P. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995, 20:1531-1534.
35. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., Wenzel R.P. Hospital acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988, 148:2642-2645.
36. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., Wenzel R.P. Risk factors for hospital-acquired candidemia. Arch Intern Med 1989, 149:2349-2353.
37. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41(9):1232-1239.